Morgan Keegan reports that it expects “strong internal NOI growth and a significant benefit going forward from the accretive addition of the HCR ManorCare master lease” from HCP, Inc. HCP.
“Various nonrecurring items affect earnings comparability in the first half of the year,” Morgan Keegan writes. “We believe the right way to look at HCP is by comparing the second half of 2012 to the second half of 2011, when we project 7%+ FAD growth absent significant acquisitions.”
HCP closed Tuesday at $39.06.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in